Top 5 Reasons to Choose Dr. Hansen’s Ashwagandha Formula

by | Jan 23, 2020


A green chalkboard with the message 'I LOVE YOU' written in white chalk.

1. Dr. Hansen has 30+ years of clinical experience. He uses Ashwagandha Roots Only! Leaf components are never added.

There are some Ashwagandha manufacturers who make their extract using the plant’s leaves instead of just the roots. However, Dr. Hansen knows the scientific research and bases his formulations on published clinical trials and sources the highest quality, standardized extracts, proven in the clinical research to be safe and effective. For this reason he chooses only KSM-66® Ashwagandha, which contains the highest concentration of the clinically proven active ingredients from roots ONLY, with no addition of leaves. This is because the preponderance of pharmacologic and clinical research shows that the maximum clinical effectiveness is obtained from the more difficult to obtain and therefore more expensive root extracts.

 

All of the standardized specifications for Ashwagandha from the Indian, the British and the U.S. Pharmacopeias are based exclusively on the root, never the leaves. There is a large number of studies documented in PubMed and conducted by universities and research hospitals, virtually all of which use root-only extracts and no leaves. While there are numerous human clinical studies using the root extract, virtually no clinical evidence for a root+leaf extract comes from published peer-reviewed research.

 

Beware of cheaper Ashwagandha products and manufacturers who do not list the actual percentage of active ingredients contained in their product, or who claim their root+leaf product is superior because it weighs more. The truth is that 300mg of 5% Active Root ONLY Ashwagandha provides more of the key active ingredients than 1300mg of a 1% product. If the product does NOT list the percentage of the key active ingredient, it is likely to contain less than 1% and be ineffective. It may also include harmful leaf toxins. (To learn more, see: Avoid Withaferin A: leaf toxin)

2. Dr. Hansen uses only KSM-66® a full-spectrum Ashwagandha extract for optimal stress relief.

Botanicals are complex substances with many constituents in them. Nature combines multiple actively beneficial ingredients into foods and herbs. Research has shown that Ashwagandha contains multiple constituents that produce its stress and anxiety relieving benefits. This combination creates a synergy of the individual constituents that produces the clinical effects. For this reason, it is important to use an Ashwagandha product that contains the “full spectrum†of all of the natural constituents. This is known as a “full-spectrum†extract, which maintains the balance of the various constituents as it is in the original herb, without over-representing any one constituent, such as the Withanolides. Dr. Hansen uses KSM-66® Ashwagandha because it is the highest quality, full spectrum extract available. It is different from other chemical or alcoholic extracts because of its innovative extraction process that does not upset the delicate balance of various constituents found in natural ashwagandha root; rather, it retains and potentiates the synergism of the whole root. This superiority is demonstrated in its extensive clinical research and double-blind clinical trials.

3. Dr. Hansen uses the highest Standardized Active Ingredients (>5% Withanolides) confirmed by HPLC.

 

When selecting an Ashwagandha product, make sure that the Withanolide content is neither too high nor too low. Having higher percentage of Withanolides (eg: 10%) is not desirable as it would upset the synergistic balance nature provides and produce suppression of the other important and protective constituents. Having too low percentage of Withanolides (eg: less than 2.5%) is also not desirable as it would require a higher dosage for consumption. KSM-66® Ashwagandha’s unique extraction process yields optimum percentage of Withanolides, retaining all of the important bioactives components of the plant, which are required for optimum safety and efficacy.

 

The vast majority of manufacturers across the world estimate Withanolide content by gravimetric analysis, which does not provide accurate results. Unfortunately, gravimetric analysis often overestimates Withanolide content by a factor of 2.5 to 3! This is because gravimetry does not adequately discriminate between Withanolides and some other constituents, thereby bundling Withanolides with other compounds and over-assessing the extent of Withanolides. Furthermore, gravimetric analysis is not reliable.

 

Dr. Hansen uses KSM-66® Ashwagandha because every batch is Standardized according to the most reliable HPLC methods of Withanolide assessment. This method is the most discriminating and accurate method of testing for active ingredient standards. KSM-66® Withanolide content as measured by HPLC is found to be >5% concentration in every batch.

4. Dr. Hansen’s uses only KSM-66® Ashwagnadha to eliminate the cyto-toxic Withaferin A that is high in products made with leaves.

Not all withanolides are beneficial. Withaferin A is one withanolide which is cytotoxic, as has been established in multiple scientific studies. Some Ashwagandha extracts have high levels of Withaferin A because the manufacturers use Ashwagandha leaves. Using leaves spikes up the overall withanolide content, but it also brings in the undesirable withanolide ‘Withaferin A’. KSM-66® Ashwagandha used by Dr. Hansen in Tranquil Clarity consists of negligible levels of Withaferin A, making it very safe for human consumption.

5. Dr. Hansen uses KSM-66® Ashwagandha exclusively because it has has been used in more clinical studies than any other brand.

KSM-66® Ashwagandha is used in more clinical trials investigating the safety and effectiveness of Ashwagandha than any other brand. It is the Ashwagandha extract with the most extensive set of research studies. Most other Ashwagandha manufacturers’ clinical trials are not published in PubMed accepted journals. KSM-66® Ashwagandha clinical trials are conducted by well-established physicians and scientists with strong publication record

Ivermectin + Mebendazole taken together produce remarkably Positive Clinical Cancer Benefits in 84.4% of Patients.

The largest real-world human analysis to date evaluating ivermectin and mebendazole in cancer patients has just been published—and the results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.

This groundbreaking analysis was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel (Dr. Harvey Risch)—uniting real-world clinical data, frontline medical experience, and high-level epidemiologic expertise to deliver urgently needed insights in oncology.

This was a real-world prospective clinical program evaluation of 197 cancer patients, with 122 completing a follow-up survey at about six months (61.9% response rate).

Cancer patients were prescribed compounded ivermectin–mebendazole, with each capsule containing 25 mg ivermectin and 250 mg mebendazole—most commonly taken at 1–2 capsules per day.

The cohort represented a clinically relevant population, including a wide variety cancer types, with 37.1% of patients reporting actively progressing disease at baseline and many having already undergone chemotherapy, radiation, and surgery.

At six months, 84.4% of cancer patients reported clinical benefit (Clinical Benefit Ratio: 84.4% [95% CI: 77.0–89.8%]):

✅ 32.8% reported NO evidence of cancer (95% CI: 25.1–41.5%)
✅ 15.6% reported tumor regression (95% CI: 10.2–23.0%)
✅ 36.1% reported stable disease (95% CI: 28.1–44.9%)

Treatment adherence was high, with 86.9% completing the full protocol and 66.4% remaining on therapy at six months.

The regimen was well tolerated, with 25.4% reporting side effects, primarily mild and gastrointestinal, and over 93% continuing treatment despite these events.

Patients were treated in real-world conditions alongside concurrent therapies, including chemotherapy (27.9%), radiation (21.3%), surgery (19.7%), supplements (49.2%), and dietary modification (37.7%), supporting use as an adjunctive approach.

Together, these findings represent a large, internally consistent real-world clinical signal that supports URGENT further investigation of ivermectin and mebendazole as low-toxicity, adjunctive cancer therapies.

Given the strength of the signal observed here, advancing this line of investigation is no longer optional—it is necessary.

This is NOT the end. We will continue advancing this work with larger datasets to further define and validate the role of anti-parasitics in cancer outcomes.

The manuscript is now available as a preprint on the Zenodo research repository, operated by the European Organization for Nuclear Research, while undergoing peer review at leading oncology journals: “Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort.”

Bar chart showing distribution of common cancer types with breast cancer most prevalent.
Infographic on disease status and median duration since diagnosis.

Receive Our Newsletter

7 + 11 =

jQuery( document ).ready(function( $ ) { // $( "div" ).hide(); });